Clinically, breast cancers are categorized into three basic therapeutic groups, which include: estrogen receptor (ER) positive group, which is the most diverse and numerous, the HER2 amplified group with effective therapeutic targeting of Her2, and the triple-negative breast cancer with only chemotherapy options and have a high incidence of BRAC1 mutation in the patients. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.